Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma

Table 4 Comparison of tumor markers (mean ± SD)

Group	AFP (μg/L)		GP-73 (μg/L)		AFP-L3 (μg/L)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control group (n = 50)	84.61 ± 5.34	33.94 ± 6.24	89.17 ± 5.27	63.08 ± 6.62	151.99 ± 31.64	117.43 ± 34.94
Observation group (n = 50)	85.17 ± 5.18	17.49 ± 4.16a	90.82 ± 6.04	47.67 ± 6.15a	154.94 ± 30.48	81.43 ± 27.95a
t value	0.532	15.510	1.456	12.050	0.474	5.689
P value	0.596	< 0.001	0.149	< 0.001	0.636	< 0.001

^aP < 0.05 compared with the control group.